Genetically Modified T Cells Obliterate Chronic Lymphocytic Leukemia Tumors

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
2,403
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Aug 31, 2011

Researchers at Penn's Abramson Cancer Center have molecularly engineered T-cells from patients with chronic lymphocytic leukemia and achieved an exceptional, unprecedented antitumor response.

In the pilot study of three patients, two achieved complete remission and the third experienced remarkable antitumor response, which was impossible with previously available treatments. The modified T-cells mimic bone marrow transplant (BMT), but without the associated risks.

The result of integration between the research lab and clinic, this study is the first time that researchers have shown that T-cells can function as serial tumor kills. In the pilot study, the modified T-cells eradicated at least 1,000 tumor cells in each patient.

Contrary to other treatments, such as chemotherapy, the modified T-cells are only released into the body once. They persist, divide and continue to kill tumor cells on their own.

View the full news release from Penn Medicine: http://www.uphs.upenn.edu/news/News_Releases/2011/08/t-cells/

Link to this comment:

Share to:
see all

All Comments (2)

Sign In or Sign Up now to post a comment!
  • I have CLL too as does my father. Hope is such a precious thing for cancer patients as rufflesme2011 shares. This great work by some amazing doctors should give all 12,000,000 living with cancer in the US and the millions more battling cancer around the world HOPE.

  • As a person with CLL this gives me great hope, if not for me but for those in the future.

Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more